anti-CD135 / FLT3 antibody [BV10A4] (PE)

anti-CD135 / FLT3 antibody [BV10A4] (PE) for Flow cytometry and Human

Immune System antibody; Signaling Transduction antibody


Product Description PE-conjugated Mouse Monoclonal antibody [BV10A4] recognizes CD135 / FLT3
Tested Reactivity Hu
Species Does Not React With Ms
Tested Application FACS
Specificity The mouse monoclonal antibody BV10A4 (BV10) reacts with CD135 (FLT3, FLK2, STK1), a 130160 kDa type III receptor tyrosine kinase that is involved in early steps of hematopoiesis.
Host Mouse
Clonality Monoclonal
Clone BV10A4
Isotype IgG1
Target Name CD135 / FLT3
Immunogen BV-173 leukemic cell line
Conjugation PE
Alternate Names CD135; FLK2; Receptor-type tyrosine-protein kinase FLT3; FLK-2; STK-1; STK1; FL cytokine receptor; FLT-3; Stem cell tyrosine kinase 1; Fetal liver kinase-2; Fms-like tyrosine kinase 3; CD antigen CD135; EC

Application Instructions

Application Suggestion
Tested Application Dilution
FACS20 µl / 10^6 cells
Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.


Form Liquid
Purification Note The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Buffer PBS, 15 mM Sodium azide and 0.2% (w/v) high-grade protease free BSA
Preservative 15 mM Sodium azide
Stabilizer 0.2% (w/v) high-grade protease free BSA
Storage Instruction Aliquot and store in the dark at 2-8°C. Keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note For laboratory research only, not for drug, diagnostic or other use.


Database Links

GeneID: 2322 Human FLT3

Swiss-port # P36888 Human Receptor-type tyrosine-protein kinase FLT3

Gene Symbol FLT3
Gene Full Name fms-related tyrosine kinase 3
Background CD135 / FLT3, also known as FLK2 or STK-1 is a receptor tyrosine kinase that plays important roles in hematopoiesis. After binding of Flt3 ligand (FL), CD135 homodimerizes and stimulates proliferation, differentiation and protects the cell from apoptosis. The loss of CD90 and gain of CD135 expression marks the loss of self-renewal in hematopoietic stem cell population. Detectable CD135 expression appears first at low levels on the surface of primitive multilineage progenitor cells and disappears during defined stages of B-cell development, but is upregulated and maintained during maturation of monocytes. CD135 is also expressed on thymocytes, dendritic cell progenitors and on mature dendritic cells, as well as on various malignant hematopoietic cells.
Function Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways. [UniProt]
Research Area Immune System antibody; Signaling Transduction antibody
Calculated MW 113 kDa
PTM N-glycosylated, contains complex N-glycans with sialic acid.
Autophosphorylated on several tyrosine residues in response to FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant kinases that are constitutively activated. Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12. Dephosphorylation is important for export from the endoplasmic reticulum and location at the cell membrane.
Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein ligase SIAH1 after autophosphorylation, leading to its proteasomal degradation.

Clone References

Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand.

Haylock DN et al.
Blood.,  (1997)